Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 238

1.

Mismatch repair deficiency identifies patients with high-intermediate-risk (HIR) endometrioid endometrial cancer at the highest risk of recurrence: A prognostic biomarker.

Backes FJ, Haag J, Cosgrove CM, Suarez A, Cohn DE, Goodfellow PJ.

Cancer. 2018 Dec 18. doi: 10.1002/cncr.31901. [Epub ahead of print]

PMID:
30561762
2.

Outpatient desensitization of patients with moderate (high-risk) to severe platinum hypersensitivity reactions.

Vetter MH, Khan A, Backes FJ, Bixel K, Cohn DE, Copeland LJ, Fowler JM, Salani R, Li Q, O'Malley DM.

Gynecol Oncol. 2018 Nov 29. pii: S0090-8258(18)31352-0. doi: 10.1016/j.ygyno.2018.10.037. [Epub ahead of print]

PMID:
30503265
3.

Pilot randomized controlled trial of a symptom cluster intervention in advanced cancer.

Wells-Di Gregorio SM, Marks DR, DeCola J, Peng J, Probst D, Zaleta A, Benson D, Cohn DE, Lustberg M, Carson WE, Magalang U.

Psychooncology. 2018 Oct 18. doi: 10.1002/pon.4912. [Epub ahead of print]

PMID:
30335211
4.

Time to chemotherapy in ovarian cancer: Compliance with ovarian cancer quality indicators at a National Cancer Institute-designated Comprehensive Cancer Center.

ElNaggar AC, Hade EM, O'Malley DM, Liang MI, Copeland LJ, Fowler JM, Salani R, Backes FJ, Cohn DE.

Gynecol Oncol. 2018 Dec;151(3):501-505. doi: 10.1016/j.ygyno.2018.09.014. Epub 2018 Sep 30.

PMID:
30282591
5.

Microfluidic affinity separation chip for selective capture and release of label-free ovarian cancer exosomes.

Hisey CL, Dorayappan KDP, Cohn DE, Selvendiran K, Hansford DJ.

Lab Chip. 2018 Oct 9;18(20):3144-3153. doi: 10.1039/c8lc00834e.

PMID:
30191215
6.

Is it reasonable to administer pegfilgrastim on day 1 of a myelosuppressive chemotherapy regimen? A cost-utility analysis.

Billingsley CC, Cohn DE, Crim AK, Li Q, O'Malley DM, Havrilesky LJ.

Cancer Treat Res Commun. 2018;14:21-25. doi: 10.1016/j.ctarc.2017.11.003. Epub 2017 Nov 10.

PMID:
30104004
7.

Receipt of adjuvant endometrial cancer treatment according to race: an NRG Oncology/Gynecologic Oncology Group 210 Study.

Felix AS, Cohn DE, Brasky TM, Zaino R, Park K, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel CI, Boggess JF, Pearl ML, Ioffe OB, Randall ME, Brinton LA.

Am J Obstet Gynecol. 2018 Nov;219(5):459.e1-459.e11. doi: 10.1016/j.ajog.2018.08.002. Epub 2018 Aug 7.

PMID:
30096321
8.

Functional characterization of recurrent FOXA2 mutations seen in endometrial cancers.

Neff R, Rush CM, Smith B, Backes FJ, Cohn DE, Goodfellow PJ.

Int J Cancer. 2018 Dec 1;143(11):2955-2961. doi: 10.1002/ijc.31784. Epub 2018 Sep 29.

PMID:
30091462
9.

Hyperthermic intraperitoneal chemotherapy (HIPEC) is cost-effective in the management of primary ovarian cancer.

Behbakht K, Cohn DE, Straughn JM Jr.

Gynecol Oncol. 2018 Oct;151(1):4-5. doi: 10.1016/j.ygyno.2018.07.019. Epub 2018 Jul 30. No abstract available.

PMID:
30068488
10.

Detection of endometrial cancer cells in the fallopian tube lumen is associated with adverse prognostic factors and reduced survival.

Felix AS, Sinnott JA, Vetter MH, Rhoades J, Cohn DE, Backes FJ, Sherman ME, Suarez AA.

Gynecol Oncol. 2018 Jul;150(1):38-43. doi: 10.1016/j.ygyno.2018.05.005. Epub 2018 May 10.

PMID:
29754740
11.

Hypoxia-induced exosomes contribute to a more aggressive and chemoresistant ovarian cancer phenotype: a novel mechanism linking STAT3/Rab proteins.

Dorayappan KDP, Wanner R, Wallbillich JJ, Saini U, Zingarelli R, Suarez AA, Cohn DE, Selvendiran K.

Oncogene. 2018 Jul;37(28):3806-3821. doi: 10.1038/s41388-018-0189-0. Epub 2018 Apr 11.

12.

Society of Gynecologic Oncology Future of Physician Payment Reform Task Force report: The Endometrial Cancer Alternative Payment Model (ECAP).

Ko EM, Havrilesky LJ, Alvarez RD, Zivanovic O, Boyd LR, Jewell EL, Timmins PF 3rd, Gibb RS, Jhingran A, Cohn DE, Dowdy SC, Powell MA, Chalas E, Huang Y, Rathbun J, Wright JD.

Gynecol Oncol. 2018 May;149(2):232-240. doi: 10.1016/j.ygyno.2018.02.010. Epub 2018 Mar 13.

PMID:
29544708
13.

Estimating potential for savings for low risk endometrial cancer using the Endometrial Cancer Alternative Payment Model (ECAP): A companion paper to the Society of Gynecologic Oncology Report on the Endometrial Cancer Alternative Payment Model.

Wright JD, Havrilesky LJ, Cohn DE, Huang Y, Rathbun J, Rice LW, Brown CL, Alvarez RD, Ko EM.

Gynecol Oncol. 2018 May;149(2):241-247. doi: 10.1016/j.ygyno.2018.02.011. Epub 2018 Mar 1.

PMID:
29496293
14.

STAT3/PIAS3 Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube.

Saini U, Suarez AA, Naidu S, Wallbillich JJ, Bixel K, Wanner RA, Bice J, Kladney RD, Lester J, Karlan BY, Goodfellow PJ, Cohn DE, Selvendiran K.

Cancer Res. 2018 Apr 1;78(7):1739-1750. doi: 10.1158/0008-5472.CAN-17-1671. Epub 2018 Jan 16.

PMID:
29339537
15.

Cancer care delivery research in gynecologic oncology.

Shalowitz DI, Cohn DE.

Gynecol Oncol. 2018 Mar;148(3):445-448. doi: 10.1016/j.ygyno.2017.12.027. Epub 2018 Jan 10. No abstract available.

PMID:
29331372
16.

MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization.

Walker CJ, Rush CM, Dama P, O'Hern MJ, Cosgrove CM, Gillespie JL, Zingarelli RA, Smith B, Stein ME, Mutch DG, Shakya R, Chang CW, Selvendiran K, Song JW, Cohn DE, Goodfellow PJ.

J Natl Cancer Inst. 2018 May 1;110(5):517-526. doi: 10.1093/jnci/djx238.

17.

An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

Cosgrove CM, Tritchler DL, Cohn DE, Mutch DG, Rush CM, Lankes HA, Creasman WT, Miller DS, Ramirez NC, Geller MA, Powell MA, Backes FJ, Landrum LM, Timmers C, Suarez AA, Zaino RJ, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ.

Gynecol Oncol. 2018 Jan;148(1):174-180. doi: 10.1016/j.ygyno.2017.10.037. Epub 2017 Nov 11.

18.

Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study.

Felix AS, Brasky TM, Cohn DE, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel C, Boggess JF, Pearl ML, Ioffe OB, Deng W, Miller DS, Brinton LA.

Int J Cancer. 2018 Mar 15;142(6):1102-1115. doi: 10.1002/ijc.31127. Epub 2017 Nov 6.

PMID:
29063589
19.

ASCO Value Framework Highlights the Relative Value of Treatment Options in Ovarian Cancer.

Foote J, Secord AA, Liang M, Cohn DE, Jewell E, Havrilesky LJ.

J Oncol Pract. 2017 Dec;13(12):e1030-e1039. doi: 10.1200/JOP.2017.025106. Epub 2017 Oct 10.

PMID:
29016225
20.

Novel SOX17 frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations.

Walker CJ, O'Hern MJ, Serna VA, Kurita T, Miranda MA, Sapp CE, Mutch DG, Cohn DE, Goodfellow PJ.

Oncotarget. 2017 Aug 12;8(40):68758-68768. doi: 10.18632/oncotarget.20213. eCollection 2017 Sep 15.

21.

Primum non nocere: Are we ready for POLE testing in endometrial cancer?

Cosgrove CM, Cohn DE, Goodfellow PJ.

Gynecol Oncol. 2017 Nov;147(2):240-242. doi: 10.1016/j.ygyno.2017.09.015. Epub 2017 Sep 22. No abstract available.

22.

Cardiovascular disease mortality among women with endometrial cancer in the Iowa Women's Health Study.

Felix AS, Blair CK, Lehman A, Bower JK, Raman SV, Lazovich D, Cohn DE, Prizment AE.

Cancer Causes Control. 2017 Oct;28(10):1043-1051. doi: 10.1007/s10552-017-0953-4. Epub 2017 Sep 1.

PMID:
28864924
23.

Genetic consultation embedded in a gynecologic oncology clinic improves compliance with guideline-based care.

Senter L, O'Malley DM, Backes FJ, Copeland LJ, Fowler JM, Salani R, Cohn DE.

Gynecol Oncol. 2017 Oct;147(1):110-114. doi: 10.1016/j.ygyno.2017.07.141. Epub 2017 Aug 8.

PMID:
28800943
24.

Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.

Cohn DE, Sill MW, Walker JL, O'Malley D, Nagel CI, Rutledge TL, Bradley W, Richardson DL, Moxley KM, Aghajanian C.

Gynecol Oncol. 2017 Sep;146(3):477-483. doi: 10.1016/j.ygyno.2017.07.135. Epub 2017 Jul 27.

25.

Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.

Cosgrove CM, Cohn DE, Hampel H, Frankel WL, Jones D, McElroy JP, Suarez AA, Zhao W, Chen W, Salani R, Copeland LJ, O'Malley DM, Fowler JM, Yilmaz A, Chassen AS, Pearlman R, Goodfellow PJ, Backes FJ.

Gynecol Oncol. 2017 Sep;146(3):588-595. doi: 10.1016/j.ygyno.2017.07.003. Epub 2017 Jul 11.

26.

Race-specific molecular alterations correlate with differential outcomes for black and white endometrioid endometrial cancer patients.

Bateman NW, Dubil EA, Wang G, Hood BL, Oliver JM, Litzi TA, Gist GD, Mitchell DA, Blanton B, Phippen NT, Tian C, Zahn CM, Cohn DE, Havrilesky LJ, Berchuck A, Shriver CD, Darcy KM, Hamilton CA, Conrads TP, Maxwell GL.

Cancer. 2017 Oct 15;123(20):4004-4012. doi: 10.1002/cncr.30813. Epub 2017 Jun 27.

27.

Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.

Bixel K, Saini U, Kumar Bid H, Fowler J, Riley M, Wanner R, Deepa Priya Dorayappan K, Rajendran S, Konishi I, Matsumura N, Cohn DE, Selvendiran K.

Int J Cancer. 2017 Nov 1;141(9):1856-1866. doi: 10.1002/ijc.30847. Epub 2017 Jul 24.

28.

Cost-effectiveness of opportunistic salpingectomy for ovarian cancer prevention.

Dilley SE, Havrilesky LJ, Bakkum-Gamez J, Cohn DE, Michael Straughn J Jr, Caughey AB, Rodriguez MI.

Gynecol Oncol. 2017 Aug;146(2):373-379. doi: 10.1016/j.ygyno.2017.05.034. Epub 2017 Jun 1.

PMID:
28577884
29.

Outpatient desensitization in selected patients with platinum hypersensitivity reactions.

O'Malley DM, Vetter MH, Cohn DE, Khan A, Hays JL.

Gynecol Oncol. 2017 Jun;145(3):603-610. doi: 10.1016/j.ygyno.2017.03.015. Epub 2017 Apr 11. Review.

PMID:
28410757
30.

Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence.

Brasky TM, Felix AS, Cohn DE, McMeekin DS, Mutch DG, Creasman WT, Thaker PH, Walker JL, Moore RG, Lele SB, Guntupalli SR, Downs LS, Nagel CI, Boggess JF, Pearl ML, Ioffe OB, Park KJ, Ali S, Brinton LA.

J Natl Cancer Inst. 2017 Mar 1;109(3):1-10. doi: 10.1093/jnci/djw251.

31.

Dose Dense Chemotherapy for Front-line Ovarian Cancer Treatment: The Price is Right?

Herzog TJ, Cohn DE.

Gynecol Oncol. 2017 Apr;145(1):1-2. doi: 10.1016/j.ygyno.2017.03.001. No abstract available.

PMID:
28317558
32.

The "value" of value in gynecologic oncology practice in the United States: Society of Gynecologic Oncology evidence-based review and recommendations.

Cohn DE, Ko E, Meyer LA, Wright JD, Temkin SM, Foote J, Jones NL, Havrilesky LJ.

Gynecol Oncol. 2017 Apr;145(1):185-191. doi: 10.1016/j.ygyno.2017.02.024. Epub 2017 Mar 1. Review. No abstract available.

33.

Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group study.

Mai PL, Piedmonte M, Han PK, Moser RP, Walker JL, Rodriguez G, Boggess J, Rutherford TJ, Zivanovic O, Cohn DE, Thigpen JT, Wenham RM, Friedlander ML, Hamilton CA, Bakkum-Gamez J, Olawaiye AB, Hensley ML, Greene MH, Huang HQ, Wenzel L.

Gynecol Oncol. 2017 Apr;145(1):122-129. doi: 10.1016/j.ygyno.2017.02.008. Epub 2017 Feb 10.

34.

Recruiting Endometrial Cancer Survivors to Studies Examining Lifestyle Behaviors and Quality of Life: Challenges Faced and Lessons Learned.

Lucas AR, Focht BC, Cohn DE, Klatt MD, Buckworth J.

J Cancer Educ. 2018 Aug;33(4):857-864. doi: 10.1007/s13187-017-1187-6.

PMID:
28188570
35.

Recurrent low grade serous ovarian cancer in a 20 year old woman: A case from the Ohio State University College of Medicine.

Cohn DE, Backes FJ, Wallbillich JJ, Bixel K, Crafton SM, Neff R, ElNaggar AC, Smith B, Suarez AA.

Gynecol Oncol. 2017 Mar;144(3):451-455. doi: 10.1016/j.ygyno.2017.01.023. Epub 2017 Feb 1.

PMID:
28161140
36.

High Glucose-Mediated STAT3 Activation in Endometrial Cancer Is Inhibited by Metformin: Therapeutic Implications for Endometrial Cancer.

Wallbillich JJ, Josyula S, Saini U, Zingarelli RA, Dorayappan KD, Riley MK, Wanner RA, Cohn DE, Selvendiran K.

PLoS One. 2017 Jan 23;12(1):e0170318. doi: 10.1371/journal.pone.0170318. eCollection 2017.

37.

HDAC10 as a potential therapeutic target in ovarian cancer.

Islam MM, Banerjee T, Packard CZ, Kotian S, Selvendiran K, Cohn DE, Parvin JD.

Gynecol Oncol. 2017 Mar;144(3):613-620. doi: 10.1016/j.ygyno.2017.01.009. Epub 2017 Jan 7.

38.

Cost Comparison of Genetic Testing Strategies in Women With Epithelial Ovarian Cancer.

Foote JR, Lopez-Acevedo M, Buchanan AH, Secord AA, Lee PS, Fountain C, Myers ER, Cohn DE, Reed SD, Havrilesky LJ.

J Oncol Pract. 2017 Feb;13(2):e120-e129. doi: 10.1200/JOP.2016.011866. Epub 2017 Jan 3.

PMID:
28045615
39.

Reproductive counseling, contraception, and unplanned pregnancy in fertile women treated by gynecologic oncologists.

Crafton SM, Lynch CD, Cohn DE, Eisenhauer EL.

Gynecol Oncol Rep. 2016 Nov 24;19:22-26. doi: 10.1016/j.gore.2016.11.006. eCollection 2017 Feb.

40.

A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: an NRG Oncology Study (NCT#01281852).

Thaker PH, Salani R, Brady WE, Lankes HA, Cohn DE, Mutch DG, Mannel RS, Bell-McGuinn KM, Di Silvestro PA, Jelovac D, Carter JS, Duan W, Resnick KE, Dizon DS, Aghajanian C, Fracasso PM.

Ann Oncol. 2017 Mar 1;28(3):505-511. doi: 10.1093/annonc/mdw635.

41.

Bokhman Redux: Endometrial cancer "types" in the 21st century.

Suarez AA, Felix AS, Cohn DE.

Gynecol Oncol. 2017 Feb;144(2):243-249. doi: 10.1016/j.ygyno.2016.12.010. Epub 2016 Dec 16.

PMID:
27993480
42.

Less radical surgery for early-stage cervical cancer: Can conization specimens help identify patients at low risk for parametrial involvement?

Smith B, McCann GA, Phillips G, Backes FJ, O'Malley DM, Cohn DE, Fowler JM, Copeland LJ, Salani R.

Gynecol Oncol. 2017 Feb;144(2):290-293. doi: 10.1016/j.ygyno.2016.11.029. Epub 2016 Nov 21.

PMID:
27884514
43.

Perioperative Outcomes for Laparotomy Compared to Robotic Surgical Staging of Endometrial Cancer in the Elderly: A Retrospective Cohort.

Backes FJ, ElNaggar AC, Farrell MR, Brudie LA, Ahmad S, Salani R, Cohn DE, Holloway RW, Fowler JM, O'Malley DM.

Int J Gynecol Cancer. 2016 Nov;26(9):1717-1721. Erratum in: Int J Gynecol Cancer. 2017 Jan;27(1):193.

PMID:
27575633
44.

The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role.

Smith B, Neff R, Cohn DE, Backes FJ, Suarez AA, Mutch DG, Rush CM, Walker CJ, Goodfellow PJ.

Gynecol Oncol. 2016 Nov;143(2):398-405. doi: 10.1016/j.ygyno.2016.08.237. Epub 2016 Aug 15.

45.

Anticancer potential of diarylidenyl piperidone derivatives, HO-4200 and H-4318, in cisplatin resistant primary ovarian cancer.

ElNaggar AC, Saini U, Naidu S, Wanner R, Sudhakar M, Fowler J, Nagane M, Kuppusamy P, Cohn DE, Selvendiran K.

Cancer Biol Ther. 2016 Oct 2;17(10):1107-1115.

46.

High cardiovascular disease mortality after endometrial cancer diagnosis: Results from the Surveillance, Epidemiology, and End Results (SEER) Database.

Felix AS, Bower JK, Pfeiffer RM, Raman SV, Cohn DE, Sherman ME.

Int J Cancer. 2017 Feb 1;140(3):555-564. doi: 10.1002/ijc.30470. Epub 2016 Nov 14.

47.

The Microcystic, Elongated, and Fragmented (MELF) Pattern of Invasion: A Single Institution Report of 464 Consecutive FIGO Grade 1 Endometrial Endometrioid Adenocarcinomas.

Joehlin-Price AS, McHugh KE, Stephens JA, Li Z, Backes FJ, Cohn DE, Cohen DW, Suarez AA.

Am J Surg Pathol. 2017 Jan;41(1):49-55.

48.

Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.

Garcia-Soto AE, Java JJ, Nieves Neira W, Pearson JM, Cohn DE, Lele SB, Tewari KS, Walker JL, Alvarez Secord A, Armstrong DK, Copeland LJ.

Gynecol Oncol. 2016 Dec;143(3):484-489. doi: 10.1016/j.ygyno.2016.10.003. Epub 2016 Oct 7.

49.

A Mindfulness-Based Lifestyle Intervention for Obese, Inactive Endometrial Cancer Survivors: A Feasibility Study.

Lucas AR, Focht BC, Cohn DE, Buckworth J, Klatt MD.

Integr Cancer Ther. 2017 Sep;16(3):263-275. doi: 10.1177/1534735416668257. Epub 2016 Sep 14.

50.

Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.

Vigorito E, Kuchenbaecker KB, Beesley J, Adlard J, Agnarsson BA, Andrulis IL, Arun BK, Barjhoux L, Belotti M, Benitez J, Berger A, Bojesen A, Bonanni B, Brewer C, Caldes T, Caligo MA, Campbell I, Chan SB, Claes KB, Cohn DE, Cook J, Daly MB, Damiola F, Davidson R, Pauw Ad, Delnatte C, Diez O, Domchek SM, Dumont M, Durda K, Dworniczak B, Easton DF, Eccles D, Edwinsdotter Ardnor C, Eeles R, Ejlertsen B, Ellis S, Evans DG, Feliubadalo L, Fostira F, Foulkes WD, Friedman E, Frost D, Gaddam P, Ganz PA, Garber J, Garcia-Barberan V, Gauthier-Villars M, Gehrig A, Gerdes AM, Giraud S, Godwin AK, Goldgar DE, Hake CR, Hansen TV, Healey S, Hodgson S, Hogervorst FB, Houdayer C, Hulick PJ, Imyanitov EN, Isaacs C, Izatt L, Izquierdo A, Jacobs L, Jakubowska A, Janavicius R, Jaworska-Bieniek K, Jensen UB, John EM, Vijai J, Karlan BY, Kast K, Investigators K, Khan S, Kwong A, Laitman Y, Lester J, Lesueur F, Liljegren A, Lubinski J, Mai PL, Manoukian S, Mazoyer S, Meindl A, Mensenkamp AR, Montagna M, Nathanson KL, Neuhausen SL, Nevanlinna H, Niederacher D, Olah E, Olopade OI, Ong KR, Osorio A, Park SK, Paulsson-Karlsson Y, Pedersen IS, Peissel B, Peterlongo P, Pfeiler G, Phelan CM, Piedmonte M, Poppe B, Pujana MA, Radice P, Rennert G, Rodriguez GC, Rookus MA, Ross EA, Schmutzler RK, Simard J, Singer CF, Slavin TP, Soucy P, Southey M, Steinemann D, Stoppa-Lyonnet D, Sukiennicki G, Sutter C, Szabo CI, Tea MK, Teixeira MR, Teo SH, Terry MB, Thomassen M, Tibiletti MG, Tihomirova L, Tognazzo S, van Rensburg EJ, Varesco L, Varon-Mateeva R, Vratimos A, Weitzel JN, McGuffog L, Kirk J, Toland AE, Hamann U, Lindor N, Ramus SJ, Greene MH, Couch FJ, Offit K, Pharoah PD, Chenevix-Trench G, Antoniou AC.

PLoS One. 2016 Jul 27;11(7):e0158801. doi: 10.1371/journal.pone.0158801. eCollection 2016.

Supplemental Content

Support Center